Enjaymo 50 mg/mL
sutimlimab-jome · INJECTION, SOLUTION, CONCENTRATE · Recordati Rare Diseases, Inc.
Enjaymo is a injection, solution, concentrate containing sutimlimab-jome at 50 mg/mL, taken intravenous. Manufactured by Recordati Rare Diseases, Inc..
Key Facts
- Brand Name
- Enjaymo
- Generic Name
- sutimlimab-jome
- NDC Code (Product)
55292-820- Manufacturer
- Recordati Rare Diseases, Inc.
- Strength
- 50 mg/mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761164
- Drug Class
- Classical Complement Pathway Inhibitor [EPC]
- Marketing Start
- 02/04/2022
Recall History
No Recall HistoryFrequently Asked Questions
What is Enjaymo used for?
Enjaymo contains sutimlimab-jome. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is Enjaymo a controlled substance?
Enjaymo is not classified as a controlled substance by the DEA.
What is the generic name for Enjaymo?
The generic name for Enjaymo is sutimlimab-jome. There are no other listed brand versions of sutimlimab-jome.
What is the NDC code for Enjaymo 50 mg/mL?
The NDC (National Drug Code) for Enjaymo 50 mg/mL is 55292-820, listed by Recordati Rare Diseases, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)